CN108348582B - 用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 - Google Patents

用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 Download PDF

Info

Publication number
CN108348582B
CN108348582B CN201680061804.XA CN201680061804A CN108348582B CN 108348582 B CN108348582 B CN 108348582B CN 201680061804 A CN201680061804 A CN 201680061804A CN 108348582 B CN108348582 B CN 108348582B
Authority
CN
China
Prior art keywords
ser
gly
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680061804.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108348582A (zh
Inventor
严海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of CN108348582A publication Critical patent/CN108348582A/zh
Application granted granted Critical
Publication of CN108348582B publication Critical patent/CN108348582B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201680061804.XA 2015-09-04 2016-09-02 用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 Active CN108348582B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214449P 2015-09-04 2015-09-04
US62/214,449 2015-09-04
US201562259061P 2015-11-24 2015-11-24
US62/259,061 2015-11-24
PCT/US2016/050183 WO2017040986A1 (en) 2015-09-04 2016-09-02 Methods for treating heart failure using glucagon receptor antagonistic antibodies

Publications (2)

Publication Number Publication Date
CN108348582A CN108348582A (zh) 2018-07-31
CN108348582B true CN108348582B (zh) 2023-04-14

Family

ID=58188491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680061804.XA Active CN108348582B (zh) 2015-09-04 2016-09-02 用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法

Country Status (7)

Country Link
US (2) US10765737B2 (cg-RX-API-DMAC7.html)
EP (1) EP3344279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6890340B6 (cg-RX-API-DMAC7.html)
CN (1) CN108348582B (cg-RX-API-DMAC7.html)
AU (1) AU2016318097B2 (cg-RX-API-DMAC7.html)
CA (1) CA2999747A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017040986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN118393150B (zh) * 2024-06-27 2024-09-13 潍坊市润生畜禽良种有限公司 一种优化gcgr卵黄抗体制备的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103983A1 (en) 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
丁淑贞等.救治原则与方法.《心内科护理学》.2015,第26页. *

Also Published As

Publication number Publication date
US20200353079A1 (en) 2020-11-12
US11446376B2 (en) 2022-09-20
JP2018528210A (ja) 2018-09-27
AU2016318097B2 (en) 2023-04-20
AU2016318097A1 (en) 2018-04-12
CA2999747A1 (en) 2017-03-09
WO2017040986A1 (en) 2017-03-09
EP3344279A1 (en) 2018-07-11
US20180256713A1 (en) 2018-09-13
US10765737B2 (en) 2020-09-08
CN108348582A (zh) 2018-07-31
JP6890340B2 (ja) 2021-06-18
JP6890340B6 (ja) 2021-07-14
EP3344279A4 (en) 2019-03-27
EP3344279B1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
CN110997726B (zh) 治疗或预防内分泌fgf-关联疾病的组合物和方法
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
JP2022177158A (ja) 心不全を処置するための組成物および方法
JP2020196750A (ja) 線維症を処置するためのセニクリビロック併用療法
EP2951205B1 (en) Anti-activin-a compounds for the treatment of ovarian cancer
JP2021506297A (ja) Wntサロゲート分子及びその使用
CN107614695B (zh) 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
JP2019504064A (ja) 抗プロ/潜在型ミオスタチン抗体およびその使用方法
TW202317175A (zh) 用於重量管理及相關代謝病症之療法
JP7374765B2 (ja) 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
AU2020319899A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP2015502975A (ja) ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
TW202319069A (zh) 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN112839672A (zh) 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
US20180244792A1 (en) Anti-fibrotic effect of cd70
JP2023506450A (ja) 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物
US20240025987A1 (en) Use of anti-il-27 antibodies
US20240166759A1 (en) Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
WO2026101890A1 (en) Combinations of anti-il-27 antibodies with toripalimab and bevacizumab
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant